Vogenx Inc. (VOGX)
NASDAQ
Closed
Sep 4, 2026
Day's Range
31.6352 wk Range
12.95Overview - VOGX - Vogenx Inc.
Key Statistics
Valuation
Enterprise Value
169.53M
EV / EBITDA
‪-113.55‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-212.22%‬
Return on Equity
‪157.26%‬
Ownership
Shares Outstanding
14.85M
Float
3.35M
Held by Insiders
‪4.74%‬
Held by Institutions
‪0.00%‬
Price stats
50-Day Avg
‪25.98‬
200-Day Avg
‪25.98‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - VOGX - Vogenx Inc.
Peers - VOGX - Vogenx Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- VOGXNASDAQVogenx Inc.471.35MMarket Cap+59.03%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt64.24BMarket Cap+25.70%52-week change40.24P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.35.60BMarket Cap-70.99%52-week change45.79P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE26.05BMarket Cap-8.41%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S17.75BMarket Cap+23.94%52-week change20.58P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.14.63BMarket Cap+27.46%52-week change-19.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.51BMarket Cap+8.62%52-week change176.46P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - VOGX - Vogenx Inc.
About
Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. The company’s current work centers on diseases linked to human metabolism dysfunction, including post-bariatric hypoglycemia and gastroparesis. Its lead product candidate,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
